Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX43 in relapsed/metastatic nasopharyngeal carcinoma after failure or intolerance of second-line therapy
CTR20250750Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in nasopharyngeal carcinoma (NPC), sponsored by HyBioPharma. Started Apr 2025; status: active.
02
Drugs
HLX43
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20250750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250750.